Downloaded 23 times
Uploaded byQuintilesIMS
The State of Oncology Innovation
The document outlines the approval of 70 new cancer treatments for over 20 tumor types, highlighting a surge in oncology research and development, with over 600 new molecules being pursued by more than 500 companies. It emphasizes the challenges faced by global health systems in adapting to new therapeutic options and the lengthy regulatory processes, which average 10.25 years from patent to approval in the U.S. The report discusses the evolution of cancer treatment and the need for collaboration among stakeholders to improve patient access to innovative therapies.
More Related Content
Similar to The State of Oncology Innovation
The State of Oncology Innovation
- 1. 70 new approved treatments For20+ tumor types 500+ companies ~600new molecules Regulatory process & timing Regulatory/ Government Clinicians FinanceHospitals PayersPatients R&D Infrastructure Reimbursement Manufacturer registration Oncology Innovation The State of Breaking down the most fertile period of oncology research and development in history. WHY ONLY 6 COUNTRIES? LEADERS IN TREATMENT Embrace the Evolution Patient Access Growth Drivers Engaged in drug development globally Late stage development to treat cancers like breast, ovarian & prostate years 5 Treatment Innovation Surge Change Cancer Treatment Trajectory Full 2016 issue of the Global Oncology Trends report —->www.theimsinstitute.org Working Together To 9.5yrs (2015) 10.25yrs (2013) Patent to approval in U.S. New science is redefining cancer as a large number of narrowly defined diseases and yielding therapeutic options for a growing number of patients. Health systems are struggling to adapt.